MA37775A1 - Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées - Google Patents
Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associéesInfo
- Publication number
- MA37775A1 MA37775A1 MA37775A MA37775A MA37775A1 MA 37775 A1 MA37775 A1 MA 37775A1 MA 37775 A MA37775 A MA 37775A MA 37775 A MA37775 A MA 37775A MA 37775 A1 MA37775 A1 MA 37775A1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- treatment
- cartilage
- compound
- pharmaceutical compositions
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical compound NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 210000000845 cartilage Anatomy 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 230000006735 deficit Effects 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 229940047124 interferons Drugs 0.000 abstract 2
- 230000036244 malformation Effects 0.000 abstract 2
- 230000007306 turnover Effects 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 101150079478 jak1 gene Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne la nouvelle utilisation médicale du composé selon la formule i, en particulier dans le traitement d'états inflammatoires, de maladies auto-immunes, de maladies de prolifération, d'allergie, de rejet de greffe, de maladies impliquant un déficit du renouvellement du cartilage, des malformations congénitales du cartilage et/ou des maladies associées à l'hypersécrétion d'il6 ou d'interférons. En particulier, le composé inhibe la famille jak de tyrosine kinases et plus particulièrement jak1. La présente invention concerne également des compositions pharmaceutiques comprenant le composé, des méthodes pour la prophylaxie et/ou le traitement de maladies impliquant des états inflammatoires, des maladies auto-immunes, des maladies de prolifération, une allergie, le rejet de greffe, des maladies impliquant le déficit du renouvellement du cartilage, des malformations congénitales du cartilage et/ou des maladies associées à l'hypersécrétion d'il6 ou d'interférons, par l'administration du composé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663520P | 2012-06-22 | 2012-06-22 | |
| PCT/EP2013/061914 WO2013189771A1 (fr) | 2012-06-22 | 2013-06-10 | Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37775A1 true MA37775A1 (fr) | 2017-04-28 |
Family
ID=48577773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37775A MA37775A1 (fr) | 2012-06-22 | 2013-06-10 | Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9284311B2 (fr) |
| EP (1) | EP2863950B1 (fr) |
| JP (2) | JP6238975B2 (fr) |
| KR (1) | KR102078069B1 (fr) |
| CN (2) | CN104379173A (fr) |
| AR (1) | AR091395A1 (fr) |
| AU (1) | AU2013279597B2 (fr) |
| BR (1) | BR112014031626A8 (fr) |
| CA (1) | CA2875619C (fr) |
| CL (1) | CL2014003462A1 (fr) |
| CO (1) | CO7160085A2 (fr) |
| CR (1) | CR20140583A (fr) |
| CY (1) | CY1120643T1 (fr) |
| DK (1) | DK2863950T3 (fr) |
| EA (1) | EA029084B1 (fr) |
| ES (1) | ES2685985T3 (fr) |
| HR (1) | HRP20181364T8 (fr) |
| HU (1) | HUE038878T2 (fr) |
| IL (1) | IL235923B (fr) |
| LT (1) | LT2863950T (fr) |
| MA (1) | MA37775A1 (fr) |
| MX (1) | MX368511B (fr) |
| MY (1) | MY177334A (fr) |
| NZ (1) | NZ702480A (fr) |
| PE (1) | PE20150187A1 (fr) |
| PH (1) | PH12014502615B1 (fr) |
| PL (1) | PL2863950T3 (fr) |
| PT (1) | PT2863950T (fr) |
| SG (2) | SG11201408123SA (fr) |
| SI (1) | SI2863950T1 (fr) |
| TW (1) | TWI586352B (fr) |
| UA (1) | UA112804C2 (fr) |
| UY (1) | UY34855A (fr) |
| WO (1) | WO2013189771A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| RS64677B1 (sr) * | 2015-04-13 | 2023-11-30 | Galapagos Nv | Metode lečenja kardiovaskularnih poremećaja |
| JP2018511620A (ja) | 2015-04-13 | 2018-04-26 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 炎症性障害の治療のための方法 |
| AU2016257892A1 (en) * | 2015-05-05 | 2017-11-09 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
| CN105061420B (zh) * | 2015-06-04 | 2017-09-05 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| WO2017106568A1 (fr) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combinaison d'un inhibiteur de jak et d'un inhibiteur de bromodomaine pour le traitement de cancers |
| WO2017106566A1 (fr) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combinaison d'un inhibiteur des jak et d'une protéine fixant mmp9 pour traiter des troubles inflammatoires |
| WO2017133423A1 (fr) * | 2016-02-02 | 2017-08-10 | 深圳市塔吉瑞生物医药有限公司 | Fig. 1 : s102 % % % diviser m ports dmrs en k groupes de ports dmrs, k et m étant des entiers positifs et k étant inférieur ou égal à m s104 % % % utilisent un précodage indépendante sur chaque groupe de ports dmrs pour transmettre dmrs |
| WO2018087202A1 (fr) | 2016-11-10 | 2018-05-17 | Galapagos Nv | Composés et compositions pharmaceutiques associées pour le traitement de maladies inflammatoires |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| SMT202400019T1 (it) | 2017-03-14 | 2024-03-13 | Galapagos Nv | Composizioni farmaceutiche comprendenti un inibitore jak |
| GB201808575D0 (en) * | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| CN113677676A (zh) * | 2019-03-30 | 2021-11-19 | 联合化学实验室有限公司 | 一种制备非戈替尼及其中间体的新方法 |
| JP7315166B2 (ja) * | 2019-06-10 | 2023-07-26 | 富士通株式会社 | グラフェンナノリボンネットワーク膜の製造方法及び電子装置の製造方法 |
| CN111686106B (zh) * | 2020-04-05 | 2022-07-15 | 温州医科大学附属第一医院 | 提高Dicer表达的化合物在制备药物中的应用 |
| CN114409675B (zh) * | 2022-01-07 | 2023-08-04 | 重庆医科大学 | 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途 |
| WO2026027676A1 (fr) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarqueurs pour déterminer le traitement de la rectocolite hémorragique avec du filgotinib |
| WO2026027669A1 (fr) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarqueurs pour déterminer le traitement de la rectocolite hémorragique avec du filgotinib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2549862T3 (es) * | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| NZ597140A (en) * | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
-
2013
- 2013-06-10 HU HUE13727625A patent/HUE038878T2/hu unknown
- 2013-06-10 MY MYPI2014703876A patent/MY177334A/en unknown
- 2013-06-10 AU AU2013279597A patent/AU2013279597B2/en active Active
- 2013-06-10 NZ NZ702480A patent/NZ702480A/en unknown
- 2013-06-10 MX MX2014014800A patent/MX368511B/es active IP Right Grant
- 2013-06-10 DK DK13727625.9T patent/DK2863950T3/en active
- 2013-06-10 HR HRP20181364TT patent/HRP20181364T8/hr unknown
- 2013-06-10 WO PCT/EP2013/061914 patent/WO2013189771A1/fr not_active Ceased
- 2013-06-10 KR KR1020157001521A patent/KR102078069B1/ko active Active
- 2013-06-10 SG SG11201408123SA patent/SG11201408123SA/en unknown
- 2013-06-10 BR BR112014031626A patent/BR112014031626A8/pt not_active Application Discontinuation
- 2013-06-10 AR ARP130102033 patent/AR091395A1/es unknown
- 2013-06-10 PL PL13727625T patent/PL2863950T3/pl unknown
- 2013-06-10 CN CN201380032159.5A patent/CN104379173A/zh active Pending
- 2013-06-10 CA CA2875619A patent/CA2875619C/fr active Active
- 2013-06-10 UY UY0001034855A patent/UY34855A/es unknown
- 2013-06-10 LT LTEP13727625.9T patent/LT2863950T/lt unknown
- 2013-06-10 PT PT13727625T patent/PT2863950T/pt unknown
- 2013-06-10 US US13/913,597 patent/US9284311B2/en active Active
- 2013-06-10 JP JP2015517666A patent/JP6238975B2/ja active Active
- 2013-06-10 SG SG10201700125VA patent/SG10201700125VA/en unknown
- 2013-06-10 SI SI201331137T patent/SI2863950T1/sl unknown
- 2013-06-10 PE PE2014002472A patent/PE20150187A1/es not_active Application Discontinuation
- 2013-06-10 CN CN201810014031.0A patent/CN107998136A/zh active Pending
- 2013-06-10 MA MA37775A patent/MA37775A1/fr unknown
- 2013-06-10 EP EP13727625.9A patent/EP2863950B1/fr active Active
- 2013-06-10 EA EA201590071A patent/EA029084B1/ru unknown
- 2013-06-10 ES ES13727625.9T patent/ES2685985T3/es active Active
- 2013-06-11 TW TW102120793A patent/TWI586352B/zh active
- 2013-10-06 UA UAA201500458A patent/UA112804C2/uk unknown
-
2014
- 2014-11-24 PH PH12014502615A patent/PH12014502615B1/en unknown
- 2014-11-26 IL IL235923A patent/IL235923B/en active IP Right Grant
- 2014-12-16 CR CR20140583A patent/CR20140583A/es unknown
- 2014-12-19 CO CO14279834A patent/CO7160085A2/es unknown
- 2014-12-19 CL CL2014003462A patent/CL2014003462A1/es unknown
-
2016
- 2016-03-14 US US15/069,130 patent/US20160296529A1/en not_active Abandoned
-
2017
- 2017-10-31 JP JP2017210372A patent/JP2018048185A/ja active Pending
-
2018
- 2018-08-29 CY CY181100902T patent/CY1120643T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502615B1 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| MA47440B1 (fr) | Sulfonylurées, composés apparentés, et leur utilisation | |
| MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
| MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
| GEP20166438B (en) | Imidazopyrrolidinone compounds | |
| MX2013012281A (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| NZ722403A (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| MX2012012328A (es) | Compuestos pirazol como inhibidores de jak. | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| IN2014CN02273A (fr) | ||
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| PH12016501677B1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MA20150279A1 (fr) | (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel | |
| MX2015001834A (es) | Nuevos compuestos antibacterianos. | |
| UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
| MX363480B (es) | Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi. | |
| EA201390764A1 (ru) | Фармацевтические композиции | |
| HK1228399A1 (en) | Protein kinase inhibitors | |
| MA38479A1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante |